Investors look at many variables when deciding which stocks to buy, including a company's industry. If an industry is exhibiting high growth, stocks in that sector can gain value. It' ...

These capabilities illustrate the multifaceted promise of AI: speeding up scientific discovery, improving patient outcomes, ...

Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for its Phase 2a ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The rapid lateral flow assay from Lumos Diagnostics distinguishes bacterial and nonbacterial respiratory infections using a drop of blood.

Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...

The benchmarking report used a rigorous methodology to ensure results reflected ICON’s true impact and performance in the competitive phase 1 landscape. ISR screened participants to ensure relevance ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Joint Press release from Bambino Gesù Children’s Hospital, Rome; Department of Biochemistry and Gurdon Institute, University ...

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...